Dexmedetomidine’s ICU Advantage: Faster Exit, Longer Stay?

jurnal.uns.ac.id November 3, 2025

This updated meta-analysis compared the outcomes of using dexmedetomidine versus other standard sedatives in mechanically ventilated patients with sepsis.

Objective: To synthesize recent evidence (2020–2025) from Randomized Controlled Trials (RCTs) comparing dexmedetomidine to other sedatives in septic, mechanically ventilated patients.

Eight RCTs involving a total of 1,119 patients.

Dexmedetomidine significantly reduced the Length of Stay (LOS) in the ICU (Mean Difference [MD] = -0.91 days, p = 0.004). The conclusion also notes it may offer early mortality benefits at 28 days.

Dexmedetomidine significantly prolonged the total hospital LOS (MD = 1.47 days, p = 0.001).

Dexmedetomidine appears effective at getting septic patients out of the ICU sooner. However, its benefit is complicated by a longer total hospital stay, and its effects on mortality, lactate clearance, and time off the ventilator remain uncertain. The authors call for more standardized trials to clarify these outcomes.